Close Menu

This article has been updated to clarify Natera's actions after it refiled its motion to invalidate CareDx's patents in April, as well as to correct a statement on John Quackenbush's views of the claims asserted in Stanford's patents.

NEW YORK – The United States District Court for the District of Delaware has denied a motion made by Natera to declare invalid three patents held by Stanford University and licensed exclusively to CareDx.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

In Nature this week: a new method for high-throughput amplicon sequencing, and more.